Poor toxicity profiles and PK/PD can quickly derail a once-promising lead, turning it into a dead end. Preventing this with rigorous ADME-Tox, kinetic characterization and target engagement studies as early as possible in the discovery pipeline can greatly increase the chances of success. Genedata Screener allows you to do this, by helping you standardize and automate analysis of your ADME/DMPK, toxicity assays, and mechanism-of-action studies.
Kinetic Profiling and Mechanism of Action
Mechanistic information including equilibrium and kinetic characterization is essential to successful and efficient drug discovery. Recent instrumentation advances have increased throughput and data volume of these analyses, enabling reliable kinetic information to be obtained early in the drug discovery process. Access to this information across the organization helps researchers make more informed decisions about candidate progression.
Genedata Screener for Mechanistic Analysis offers a solution for scalable processing of mechanistic assays at high throughput, enabling you to:
Eliminate multiple software packages with a single solution used from original data capture to end result calculation.
Fully automate trace processing, kinetic analysis, and curve fitting, simultaneously testing multiple inhibition and binding models for tens to hundreds of compounds.
Maintain control over your results, with clear and interactive visualizations at each level of processing from raw trace data to curve fits.
Flexibly adjust or apply new calculations, which are then instantly applied across the entire screen.
Automated patch clamp enables high-resolution cell-based measurement of ion channels—essential for important toxicity tests such as cardiac safety, at scale. While advances in high throughput electrophysiology instrumentation have led to a dramatic increase in throughput, they have also resulted in new data analysis bottlenecks when analyzing electrophysiological data.
Supporting the latest electrophysiology instrumentation, Genedata Screener for Ion Channel Screening addresses these bottlenecks, enabling you to:
Automate sophisticated normalization, averaging and fitting of time-series data, from patch-clamp experiments across millions of compounds, reducing total data handling and analysis time by upwards of 95%.
Apply any adjustments to calculation windows to downstream results on the fly, for consistent, high-quality analysis.
View electrophysiology traces from within plate-level visualizations and alongside key results, for rapid QC and assessment.
Customers such as Pfizer and Genentech use Genedata Screener to streamline and automate their high throughput patch clamp screens of up to a million compounds. Learn how AstraZeneca used Genedata Screener to automate and increase the throughput of cardiac safety screens.
ADME-Tox & DMPK
Genedata Screener customers also use the software to analyze their ADME and DMPK data, including studies of clearance, solubility, permeability and more—contact us to learn more.